Pureos Bioventures

Switzerland · Venture Capital & Private Equity

Pureos Bioventures is a venture capital fund based in Switzerland that focuses on investing in private companies involved in innovative drug development. The fund specializes in the next generation of biological drugs and novel drug formats, targeting a variety of therapeutic areas such as oncology, immunology, ophthalmology, rare diseases, and neuroscience. Pureos Bioventures aims to enhance patient outcomes by supporting the advancement of innovative treatments for serious diseases. The company provides venture capital funding to emerging biotech firms that are developing biological therapeutics. With a team experienced in investment, clinical development, and operations, Pureos Bioventures assists its portfolio companies in bringing new therapies to market. The leadership team includes experts like Dr. Martin Münchbach and Dr. Veronica Gambillara Fonck, who bring extensive backgrounds in protein chemistry and biotech management. Pureos Bioventures is dedicated to backing companies that demonstrate scientific excellence and the potential to create breakthrough therapies across multiple disease areas.